Author

A. D. Garg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Approach:deep learning· 2 Organism:human· 2 Organism:mouse· 2 Approach:statistical model· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

I. Vanmeerbeek· 3 shared J. Borst· 2 shared J. Sprooten· 2 shared L. Boon· 2 shared S. De Vleeschouwer· 2 shared S. Janssens· 2 shared S. Naulaerts· 2 shared S. Tejpar· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

I. Vanmeerbeek

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A lymph node-to-tumour PD-L1+macrophage circuit antagonizes dendritic cell immunotherapy

J. Sprooten, I. Vanmeerbeek, A. Datsi, J. Govaerts, D. Borras, S. Naulaerts, R. Laureano, A. Calvet, M. Kuballa, M. Sabel, M. Rapp, C. Knobbe-Thomsen, P. Liu, L. Zhao, O. Kepp, , A. D. Garg

This paper shows that DC vaccines can activate PD-L1+ macrophages in lymph nodes and tumors, creating an immunosuppressive circuit that limits their effectiveness, but this can be overcome by combining with PD-L1 blockade.

Cell Reports Medicine · Jan 1, 2024Peer-reviewedImmunology

Distinct cDC subsets co-operate in CD40 agonist response while suppressive microenvironments and lack of antigens subvert efficacy

A. Murgaski, M. Kiss, H. Van Damme, D. Kancheva, I. Vanmeerbeek, J. Keirsse, E. Hadadi, J. Brughmans, S. M. Arnouk, A. E. I. Hamouda, A. Debraekeleer, V. Bosteels, Y. Elkrim, L. Boon, S. Hoves, , D. Laoui

This study identifies cDC subsets that cooperate in CD40 agonist response and shows that suppressive microenvironments and antigen scarcity limit its efficacy in cancer.

bioRxiv · Dec 25, 2021 · PreprintCancer Biology

Immunogenomic, single-cell and spatial dissection of CD8+T cell exhaustion reveals critical determinants of cancer immunotherapy

S. Naulaerts, D. M. Borras, A. A. Martinez, J. Messiaen, Y. Van Herck, L. Gelens, T. Venken, I. Vanmeerbeek, S. More, J. Sprooten, O. Bechter, G. Bergers, A. Liston, S. De Vleeschouwer, B. J. Van den Eynde, , A. D. Garg

This study identifies distinct CD8+T cell states in cancer patients using multi-omics data, showing that dysfunctional states resist immunotherapy while exhausted states can be targeted with specific treatments.

bioRxiv · Nov 22, 2021Immunology

The IRE1 Inhibitor KIRA6 Curtails The Inflammatory Trait Of Immunogenic Anticancer Treatments By Targeting HSP60 Independent Of IRE1

N. Rufo, D. Korovesis, S. van Eygen, R. Derua, A. D. Garg, F. Finotello, M. Vara Perez, J. Rozanc, M. Dewaele, P. A. de Witte, L. Alexopoulos, S. Janssens, L. Sinkkonen, T. Sauter, S. H. L. Verhelst, P. Agostinis

The paper shows KIRA6 reduces inflammation from immunogenic cancer treatments by targeting HSP60, not through IRE1 inhibition.

bioRxiv · Dec 24, 2020 · PreprintCancer Biology